The Connecticut State Legislature introduced Senate Bill 11 on April 2, 2025, aiming to enhance access to affordable medications through the regulation of 340B drug pricing. This bill seeks to address concerns regarding the acquisition and delivery of 340B drugs by covered entities, which include The University of Connecticut Health Center and various federally qualified health centers.

Key provisions of the bill prohibit manufacturers and their affiliates from denying or restricting the acquisition of 340B drugs by pharmacies authorized by covered entities. Additionally, it prevents manufacturers from requiring these entities to submit claims or utilization data as a condition for drug acquisition, unless mandated by federal law. This aims to streamline processes and ensure that covered entities can effectively serve their patients without unnecessary barriers.

The bill has sparked notable debates among stakeholders. Proponents argue that it is essential for maintaining the integrity of the 340B program, which is designed to provide discounted medications to vulnerable populations. They emphasize that the bill will help prevent discriminatory practices by manufacturers that could limit access to necessary medications. Conversely, some manufacturers and industry representatives have expressed concerns about the potential for increased regulatory burdens and the implications for drug pricing structures.

The economic implications of Senate Bill 11 could be significant, as it aims to protect the financial viability of health centers that rely on the 340B program to provide affordable care. By ensuring that these entities can access medications without undue restrictions, the bill may help improve health outcomes for low-income patients.

As the bill progresses through the legislative process, its future remains uncertain. Experts suggest that if passed, it could set a precedent for similar legislation in other states, potentially reshaping the landscape of pharmaceutical pricing and access to care. The Connecticut legislature is expected to continue discussions on the bill, with stakeholders closely monitoring its developments.